Blood-test monitoring lab for CAR-T and gene therapy patients after infusion
TL;DR Engraftly is a specialist lab that tracks patients after CAR-T or gene therapy using routine blood draws. It measures whether the modified cells are still present and whether the immune system is recovering, on a fixed schedule. Treating hospitals and therapy makers pay per panel. It works because Indian CAR-T use is growing faster than follow-up capacity.
India approved its first home-grown CAR-T therapy in October 2023 at about ₹30–35 lakh a patient[1]. A second followed in January 2025, and around 300 patients had received the first one by mid-2025[2]. Its maker now claims more than 130 authorised centres[3].
After infusion, doctors need to know whether the cells persist, whether B cells have been wiped out (which calls for immunoglobulin support), and whether relapse is starting. In one Indian trial about 40% of patients relapsed[2]. GlobalData lists the monitoring burden and city-bound facilities among the main access hurdles[4]. Many of the newer centres do not have specialist assays in-house.
What it does, in regulatory terms: laboratory monitoring to support the treating team. Engraftly reports measurements, and it does not diagnose relapse or recommend treatment. The haematologist interprets results.
The hospital draws blood at set points after infusion - weekly at first, then monthly, then quarterly. A cold-chain courier brings samples to Engraftly's accredited lab, which runs a panel for CAR-T or vector copy number, B-cell and T-cell counts by flow cytometry, and immunoglobulin levels. Results go back in 48–72 hours in a single trend chart per patient. Later, the same lab can serve long-term follow-up for gene therapy trials such as the haemophilia work at a large teaching hospital[5].
The seed proposed liquid biopsy plus AI, and I reframed it. The useful blood tests here are established assays, and a few hundred patients a year is far too little data for AI to add much. The value is in doing these tests reliably and in one place.
Patients already pay for the therapy, and follow-up is billed separately[6]. The buyers are treating hospitals that lack the assays and therapy makers that need post-approval data. Expect per-panel pricing for hospitals and contracts for manufacturers and trial sponsors. I found no public price for a CAR-T persistence panel in India.
Two CAR-T products are approved in India and more are in trials[2]. Indian prices are about a tenth of US prices[4], so volumes should keep rising. Gene therapy trials have started at a large Indian teaching hospital, with five patients reported in 2025[5].
No public figure exists for this monitoring market. The narrow signal is patient count: around 300 patients on the first Indian CAR-T by July 2025[2], while the company's own site shows both 200+ and 600+ patients[3]. Which one is right? Nobody outside the company can say, so ask the makers directly. Each patient needs repeated panels over the first year at least.
Therapy makers and large academic centres run some tests in-house, but publish little about it. One large genomics lab sells a liquid biopsy test for tumour DNA, which is a different measurement[7]. I found no independent Indian lab openly offering a CAR-T persistence and immune-recovery panel. The gap is a neutral lab that any treating centre can use.
| Difficulty | Hard (55/100) |
| Starting capital | ₹1.5–2.8 Cr |
| Time to launch | 9–15 months |
Validating assays for each product needs reference material and cooperation from the makers. You also need cold-chain logistics from dozens of hospitals, and accreditation before any hospital will rely on the results. Every sample in the first weeks after infusion is time-critical, so the operation cannot slip.
Yes. This is a medical lab, so accreditation and data rules apply before you take patient samples.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't let AI say whether a patient is relapsing. The lab reports numbers and the haematologist interprets them.
Want to work out the AI layer for Engraftly? Talk to Yash →
Here's what can go south -
I'd only back this for a founder with flow cytometry or molecular diagnostics experience and ties to haematology centres. If you're a generalist then it's the wrong idea for you. First prove that one CAR-T maker will share reference material and that three treating centres will send samples and pay per panel.
Plan for about ₹1.5–2.8 Cr, mostly flow cytometry and molecular equipment, accreditation and cold-chain logistics. The free kit has the line-by-line capital breakdown.
You need NABL ISO 15189 accreditation and DPDP compliance. CDSCO IVD licensing only applies if you sell a kit.
Yes, wherever CAR-T is given outside big academic centres. Check local lab accreditation and health data law first.
The free Engraftly validation kit has the line-by-line capital breakdown, the effort scoring, the lab accreditation and data-protection checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for haematologists and therapy makers, and 5 assumptions to test. Download the kit →
Thinking about building Engraftly or something close to it? The make-or-break work is winning the trust of CAR-T makers and treating centres at the same time, which is no easy task. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.